Disease · MONDO_0017991

Takayasu arteritis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Takayasu arteritis. Diseases, record MONDO_0017991. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0017991

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Takayasu arteritis; Open Targets
Open Targets ID: MONDO_0017991; Open Targets
Other names: Arteritis, Takayasu, Takayasu's arteritis, Takayasu's disease, aortic arch arteritis, aortic arch syndrome, cervical aortic arch, idiopathic aortitis, pharyngeal arch artery syndromic disease; Open Targets
Disease Ontology: DOID:2508; Disease Ontology
MeSH: D013625; MeSH
NCI Thesaurus: C34391; NCI Thesaurus
NCI Thesaurus: C35062; NCI Thesaurus
Orphanet: ORPHA:3287; Orphanet
Orphanet: ORPHA:99079; Orphanet
Highest stage of its drugs: Phase 3, for 9 of its 19 drugs, from ClinicalTrials.gov; Open Targets

Drugs19

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TOCILIZUMAB	CHEMBL1237022	Antibody	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	3	3	2	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
MYCOPHENOLATE MOFETIL	CHEMBL1456	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISOLONE	CHEMBL131	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
TOFACITINIB	CHEMBL221959	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
UPADACITINIB	CHEMBL3622821	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
USTEKINUMAB	CHEMBL1201835	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 19

See all 19 drugs

Targets21

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
JAK1	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Phase 3	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Phase 3	https://conductscience.org/library/genes/3717	Drugs and targets
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
TNF	Tumor necrosis factor	3	TNF-alpha inhibitor	Phase 2	https://conductscience.org/library/genes/7124	Drugs and targets
JAK3	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Phase 3	https://conductscience.org/library/genes/3718	Drugs and targets
TYK2	Janus Kinase (JAK)	2	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor	Phase 3	https://conductscience.org/library/genes/7297	Drugs and targets
CD80	T-lymphocyte activation antigen CD80	1	T-lymphocyte activation antigen CD80 inhibitor	Phase 2	https://conductscience.org/library/genes/941	Drugs and targets
CD86	T-lymphocyte activation antigen CD86	1	T-lymphocyte activation antigen CD86 inhibitor	Phase 2	https://conductscience.org/library/genes/942	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 3	https://conductscience.org/library/genes/1719	Drugs and targets
DHODH	Dihydroorotate dehydrogenase (quinone), mitochondrial	1	Dihydroorotate dehydrogenase inhibitor	Unknown	https://conductscience.org/library/genes/1723	Drugs and targets

1 to 10 of 21

See all 21 targets

Trials17

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00556439	Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis	Phase 2	97	2018-02-26	Takayasu's Arteritis, Giant Cell Arteritis	ABATACEPT	Its record names the disease	ClinicalTrials.gov
NCT04882072	A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)	Phase 3	14	2024-12-02	Takayasu Arteritis	USTEKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT03893136	The Registry Study of Takayasu Arteritis in East China		1,000		Takayasu Arteritis, Mechanisms, Defense, Pregnancy Related, Treatment Refusal, Outcome	LEFLUNOMIDE, TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03096275	Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis	Phase 3	138		Takayasu Arteritis	METHOTREXATE, MYCOPHENOLATE MOFETIL	Its record names the disease	ClinicalTrials.gov
NCT02981979	Takayasu Arteritis Clinical Trial in China	Not applicable	116		Takayasu Arteritis	LEFLUNOMIDE, PREDNISONE	Its record names the disease	ClinicalTrials.gov
NCT06807788	Evaluation of Platelet Aggregability in Patients with Takayasu's Arteritis		100		Takayasu Arteritis (TAK), Vasculitis, Systemic	CLOPIDOGREL	Its record names the disease	ClinicalTrials.gov
NCT01988506	Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases	Phase 2	81		Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Psoriasis, Behcet's Disease, Wegener's Granulomatosis, Takayasu's Disease, Crohn's Disease, Ulcerative Colitis, Autoimmune Hepatitis, Sclerosing Cholangitis, Gougerot-sjögren, Idiopathic Thrombocytopenic Purpura, Systemic Sclerosis	ALDESLEUKIN	Its record names the disease	ClinicalTrials.gov
NCT04161898	A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)	Phase 3	56		Takayasu Arteritis (TAK)	UPADACITINIB	Its record names the disease	ClinicalTrials.gov
NCT07477795	Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients	Phase 2	52		Takayasu Arteritis, Large Vessel Vasculitis	SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT04564001	Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis	Phase 2	50		Takayasu Arteritis	INFLIXIMAB, TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 17

See all 17 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Double-blind: Ustekinumab vs Double-blind: Placebo: Number of Participants Achieving GC Dose of 5 mg/Day or Less Through the End of Double-blind Period	1 of 6	3 of 8	14	NCT04882072	Trial comparisons
OLE: Ustekinumab Then Ustekinumab vs OLE: Placebo Then Ustekinumab: Number of Participants With Positive Anti-ustekinumab Antibodies Through End of OLE Period	0 of 6	0 of 3	9	NCT04882072	Trial comparisons

Papers from its trials17

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27924855	RESULT	1	PubMed
20054700	RESULT	1	PubMed
17332971	RESULT	1	PubMed
16221103	RESULT	1	PubMed
10068416	RESULT	1	PubMed
42399917	DERIVED	1	PubMed
42025686	DERIVED	1	PubMed
40804749	DERIVED	1	PubMed
40411764	DERIVED	1	PubMed
40104212	DERIVED	1	PubMed

1 to 10 of 17

See all 17 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0017991

GET https://conductscience.org/api/diseases/v1/MONDO_0017991/targets?page=2

API reference For AI assistants